Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M25-287 taletrectinib? No — taletuzumab? No — Telisotuzumab vedotin? No — Telisotuzumab adizutecan plus osimertinib versus standard of care in first-line EGFR-mutated non-squamous NSCLC
MOH_2025-05-07_014073Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2025
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of telisotuzumab adizutecan and osimertinib in Non-small cell lung cancer (NS-NSCLC) (4 arms), sponsored by AbbVie Inc. Started May 2025; status: recruiting.
02
Drugs
telisotuzumab adizutecanosimertinib
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on MOH_2025-05-07_014073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-05-07_014073.